EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efeitos da Tirzepatida na Doença Hepática Esteatótica associada à disfunção metabólica em pacientes com obesidade: uma revisão integrativa

Higor Andrade Bustamante, Khayra Ribeiro da Cunha Aguiar, Livia Monteiro Porto, Tarcisio Silva Sousa, Vittor Andrade Bustamante, Luciano de Oliveira Souza Tourinho, Geni Alves Casteliano

Revista ft · 14.06.2026 · 30 (159) · 01-15

DOI: 10.69849/etpxqp41 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista ft, online erschienen am 14.06.2026. Verfasst von Higor Andrade Bustamante und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Obesity-associated hepatic steatosis represents one of the major metabolic diseases of the present day, characterized by excessive fat accumulation in the liver and frequently associated with insulin resistance, metabolic syndrome, and increased cardiovascular risk. The worldwide rise in obesity has significantly contributed to the increasing prevalence of this condition, making it an important public health issue. In this context, tirzepatide, a dual GIP and GLP-1 receptor agonist, has demonstrated promising results in reducing body weight, improving metabolic parameters, and potentially reversing hepatic steatosis. Therefore, understanding the impacts of tirzepatide use in the management of obesity-associated hepatic steatosis is highly relevant.

Objectives

To analyze the available scientific evidence on the effects of tirzepatide on metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with obesity.Methodology: This study consists of a integrative literature review conducted with the aim of gathering and analyzing scientific evidence regarding the reversal of obesity-associated hepatic steatosis with the use of tirzepatide. The search was carried out in the Medical Literature Analysis and Retrieval System Online (Medline), Latin American and Caribbean Health Sciences Literature (LILACS), and Scientific Electronic Library Online (SciELO) databases. Controlled descriptors from the MeSH and DeCS vocabularies were used, such as “Tirzepatide,” “Fatty Liver,” “Obesity,” and “Metabolic Dysfunction-Associated Steatotic Liver Disease,” combined using Boolean operators (AND, OR). Articles published between 2020 and 2025, available in full text, in Portuguese, English, and Spanish, and addressing the proposed topic were included. Results and Discussion: The analyzed studies demonstrate that tirzepatide promotes significant body weight reduction, improvement in insulin resistance, and decreased hepatic fat accumulation, contributing to the reversal of hepatic steatosis in obese individuals. Improvements were observed in hepatic laboratory markers such as ALT and AST, as well as reductions in inflammatory and metabolic parameters related to the progression of fatty liver disease. The findings also highlight additional benefits, including glycemic control, reduction in abdominal circumference, and improved quality of life. However, some studies reported gastrointestinal adverse effects, such as nausea, vomiting, and diarrhea, especially at the beginning of treatment. The literature also emphasizes the need for further long-term studies to evaluate the safety, sustained efficacy, and impact of tirzepatide on the prevention of advanced hepatic complications.

Conclusion

It is concluded that tirzepatide has significant potential in reversing obesity-associated hepatic steatosis, promoting relevant metabolic and hepatic benefits. Its effects on body weight reduction and improvement in insulin resistance demonstrate an important therapeutic role in the management of metabolic dysfunction-associated steatotic liver disease. However, further studies are needed to consolidate evidence regarding its long-term safety and efficacy.

Zitieren

APA

Bustamante, H. A., Aguiar, K. R. D. C., Porto, L. M., Sousa, T. S., Bustamante, V. A., Tourinho, L. D. O. S., & Casteliano, G. A. (2026). Efeitos da Tirzepatida na Doença Hepática Esteatótica associada à disfunção metabólica em pacientes com obesidade: uma revisão integrativa. Revista ft, 30(159), 01-15. https://doi.org/10.69849/etpxqp41

Vancouver

Bustamante HA, Aguiar KRDC, Porto LM, Sousa TS, Bustamante VA, Tourinho LDOS, et al. Efeitos da Tirzepatida na Doença Hepática Esteatótica associada à disfunção metabólica em pacientes com obesidade: uma revisão integrativa. Revista ft. 2026;30(159):01-15. doi:10.69849/etpxqp41

BibTeX
@article{Bustamante2026,
  author = {Bustamante, Higor Andrade and Aguiar, Khayra Ribeiro da Cunha and Porto, Livia Monteiro and Sousa, Tarcisio Silva and Bustamante, Vittor Andrade and Tourinho, Luciano de Oliveira Souza and Casteliano, Geni Alves},
  title = {Efeitos da Tirzepatida na Doença Hepática Esteatótica associada à disfunção metabólica em pacientes com obesidade: uma revisão integrativa},
  journal = {Revista ft},
  year = {2026},
  volume = {30},
  number = {159},
  pages = {01--15},
  doi = {10.69849/etpxqp41}
}
Kostenlos starten →